<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01549041</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00029068</org_study_id>
    <nct_id>NCT01549041</nct_id>
  </id_info>
  <brief_title>Once-Daily Asenapine for Schizophrenia</brief_title>
  <official_title>A Randomized Comparison of Twice-Daily Versus Once-Daily Asenapine for Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to explore: 1. the acceptance by patients of once versus twice
      daily dosing with asenapine, 2. the acceptance by staff of once versus twice daily dosing
      with asenapine, and 3. the changes in psychopathology associated with these two dosing
      strategies, in 30 patients with schizophrenia or schizoaffective disorder.

      The investigators hypothesize that patient and staff acceptance will be better with once
      daily dosing and that improvements in psychopathology will be similar across once daily and
      twice daily dosing
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will randomly assign 30 patients newly admitted to Central Regional
      Hospital (CRH) for a psychotic exacerbation of schizophrenia or schizo-affective disorder to
      14 days of treatment with either asenapine 5 mg BID or asenapine 10 mg QHS.

      The investigators will assess patient and staff acceptance on day 14. The investigators will
      assess staff acceptance on day 14. The investigators will assess changes in psychopathology
      (Brief Psychiatric Rating Scale) from baseline to day 14.

      The investigators propose to achieve the following specific aims:

        1. To compare the patient acceptance of once daily versus twice daily asenapine; The
           investigators hypothesize that patient acceptance will be better for asenapine 10 mg QHS
           than for asenapine 5 mg BID at day 14

        2. To compare the staff (medication nurses) acceptance of once daily versus twice daily
           asenapine; the investigators hypothesize that staff acceptance will be better for
           asenapine 10 mg QHS than for asenapine 5 mg BID at day 14

        3. To compare the changes in psychopathology with once daily versus twice daily asenapine;
           the investigators hypothesize that changes in psychopathology from baseline to day 14
           will be similar for the two dosing strategies
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Acceptance</measure>
    <time_frame>At day 14</time_frame>
    <description>A Patient Acceptance Likert Scale (1= Very Acceptable to 7 = Completely Unacceptable, i.e., individual refuses further doses) will be administered to the patient by the Research Nurse on day 14 of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Brief Psychiatric Rating Scale (BPRS) Total Score</measure>
    <time_frame>From baseline to day 14</time_frame>
    <description>The BPRS will be completed by the Principle Investigator at baseline and at day 14. The BPRS has 18 items each rated 1-7 with 1 representing the lowest severity of symptoms and 7 representing the highest severity; thus the lowest and highest possible total scores are 18 and 126</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>asenapine 10 mg daily in the evening</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive their entire daily dose of asenapine as a single dose in the evening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>asenapine 5 mg twice daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive asenapine 5 mg daily in the morning and 5 mg daily in the evening</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asenapine 10 mg daily in the evening</intervention_name>
    <description>The total daily dose of Asenapine will be given once daily in the evening</description>
    <arm_group_label>asenapine 10 mg daily in the evening</arm_group_label>
    <other_name>Saphris</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asenapine 5 mg twice daily</intervention_name>
    <description>Asenapine will be given in two doses, 5 mg in the morning and 5 mg in the evening, daily</description>
    <arm_group_label>asenapine 5 mg twice daily</arm_group_label>
    <other_name>Saphris</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female individuals,

          -  18-65 years of age,

          -  who meet DSM-IV diagnostic criteria for schizophrenia or schizoaffective disorder,

          -  who are newly admitted to Central Regional Hospital for treatment of an acute
             psychotic exacerbation,

          -  who provide signed informed consent to participate, will be included.

        Exclusion Criteria:

          -  Females who are lactating or pregnant,

          -  individuals with a prior history of poor therapeutic response or sensitivity to
             asenapine, will be excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Beyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Regional Hospital</name>
      <address>
        <city>Butner</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2011</study_first_submitted>
  <study_first_submitted_qc>March 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2012</study_first_posted>
  <results_first_submitted>January 24, 2014</results_first_submitted>
  <results_first_submitted_qc>April 23, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 26, 2014</results_first_posted>
  <last_update_submitted>April 23, 2014</last_update_submitted>
  <last_update_submitted_qc>April 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>asenapine</keyword>
  <keyword>Once daily</keyword>
  <keyword>twice daily</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asenapine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>30 PATIENTS PARTICIPATED AND WERE RANDOMIZED 12 WERE RANDOMIZED TO ASENAPINE 10 MG QHS 18 WERE RANTOMIZED TO ASENAPINE 5 MG BID</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Asenapine 10 mg Daily in the Evening</title>
          <description>Patients will receive their entire daily dose of asenapine as a single dose in the evening
Asenapine 10 mg once daily in the evening: The total daily dose of Asenapine will be given once daily in the evening</description>
        </group>
        <group group_id="P2">
          <title>Asenapine 5 mg Twice Daily</title>
          <description>Patients will receive asenapine 5 mg daily in the morning and 5 mg daily in the evening
Asenapine 5 mg twice daily: Asenapine will be given in two doses, 5 mg in the morning and 5 mg in the evening, daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Asenapine 10 mg Daily in the Evening</title>
          <description>Patients will receive their entire daily dose of asenapine as a single dose in the evening
Asenapine 10 mg once daily in the evening: The total daily dose of Asenapine will be given once daily in the evening</description>
        </group>
        <group group_id="B2">
          <title>Asenapine 5 mg Twice Daily</title>
          <description>Patients will receive asenapine 5 mg daily in the morning and 5 mg daily in the evening
Asenapine 5 mg twice daily: Asenapine will be given in two doses, 5 mg in the morning and 5 mg in the evening, daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.2" lower_limit="22" upper_limit="61"/>
                    <measurement group_id="B2" value="33.1" lower_limit="20" upper_limit="56"/>
                    <measurement group_id="B3" value="36.3" lower_limit="20" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patient Acceptance</title>
        <description>A Patient Acceptance Likert Scale (1= Very Acceptable to 7 = Completely Unacceptable, i.e., individual refuses further doses) will be administered to the patient by the Research Nurse on day 14 of treatment.</description>
        <time_frame>At day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Asenapine 10 mg Daily in the Evening</title>
            <description>Patients will receive their entire daily dose of asenapine as a single dose in the evening
Asenapine 10 mg once daily in the evening: The total daily dose of Asenapine will be given once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Asenapine 5 mg Twice Daily</title>
            <description>Patients will receive asenapine 5 mg daily in the morning and 5 mg daily in the evening
Asenapine 5 mg twice daily: Asenapine will be given in two doses, 5 mg in the morning and 5 mg in the evening, daily</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Acceptance</title>
          <description>A Patient Acceptance Likert Scale (1= Very Acceptable to 7 = Completely Unacceptable, i.e., individual refuses further doses) will be administered to the patient by the Research Nurse on day 14 of treatment.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.5"/>
                    <measurement group_id="O2" value="3.9" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Brief Psychiatric Rating Scale (BPRS) Total Score</title>
        <description>The BPRS will be completed by the Principle Investigator at baseline and at day 14. The BPRS has 18 items each rated 1-7 with 1 representing the lowest severity of symptoms and 7 representing the highest severity; thus the lowest and highest possible total scores are 18 and 126</description>
        <time_frame>From baseline to day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Asenapine 10 mg Daily in the Evening</title>
            <description>Patients will receive their entire daily dose of asenapine as a single dose in the evening
Asenapine 10 mg once daily in the evening: The total daily dose of Asenapine will be given once daily in the evening</description>
          </group>
          <group group_id="O2">
            <title>Asenapine 5 mg Twice Daily</title>
            <description>Patients will receive asenapine 5 mg daily in the morning and 5 mg daily in the evening
Asenapine 5 mg twice daily: Asenapine will be given in two doses, 5 mg in the morning and 5 mg in the evening, daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Brief Psychiatric Rating Scale (BPRS) Total Score</title>
          <description>The BPRS will be completed by the Principle Investigator at baseline and at day 14. The BPRS has 18 items each rated 1-7 with 1 representing the lowest severity of symptoms and 7 representing the highest severity; thus the lowest and highest possible total scores are 18 and 126</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.08" spread="2.64"/>
                    <measurement group_id="O2" value="7.72" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Asenapine 10 mg Daily in the Evening</title>
          <description>Patients will receive their entire daily dose of asenapine as a single dose in the evening
Asenapine 10 mg once daily in the evening: The total daily dose of Asenapine will be given once daily in the evening</description>
        </group>
        <group group_id="E2">
          <title>Asenapine 5 mg Twice Daily</title>
          <description>Patients will receive asenapine 5 mg daily in the morning and 5 mg daily in the evening
Asenapine 5 mg twice daily: Asenapine will be given in two doses, 5 mg in the morning and 5 mg in the evening, daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>daytime drowsiness</sub_title>
                <description>excessive sedation during the day</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size Open label design</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Joseph P McEvoy, MD</name_or_title>
      <organization>DukeUMC</organization>
      <phone>9198199295</phone>
      <email>JPMCEVOY@DUKE.EDU</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

